Asthma Biologics

What Are Asthma Biologics?

Asthma biologics are injectable medications, most often monoclonal antibodies, developed to treat severe asthma that remains poorly controlled despite standard inhaled treatment. They represent a fundamentally different approach from the medications most people with asthma use daily.

This page covers the biologic therapy class broadly (the shared concepts and reasoning that apply across agents) rather than serving as a promotional overview of any single product.

Why Biologics Are Used: A Treatment for Severe, Refractory Asthma

Biologics are not a general or first-line asthma treatment. The large majority of people with asthma achieve good control with inhaled corticosteroids, often combined with a long-acting bronchodilator, along with attention to triggers and comorbid conditions. Biologics are reserved for a smaller subset of patients, generally those with confirmed severe asthma, whose symptoms, exacerbations, or oral steroid requirements remain unacceptably high even after that standard approach has been optimized.

Before biologic therapy is considered, clinical guidelines call for confirming that poor control genuinely reflects severe, treatment-refractory disease rather than a fixable problem elsewhere. That means checking inhaler technique and reviewing adherence honestly, and identifying and treating contributing conditions that can worsen apparent asthma control without the underlying airway disease itself being undertreated, including:

• Allergic rhinitis
• Chronic sinusitis
• Gastroesophageal reflux
• Obstructive sleep apnea
• Obesity

Only once this workup confirms genuinely severe asthma does biologic therapy become a relevant consideration, generally in coordination with a pulmonologist or asthma specialist.

How a Biologic Is Selected and Started

Once severe, treatment-refractory asthma is confirmed, choosing and starting a biologic generally follows the same overall sequence, though the specific pathways and sections below fill in how each step actually works.

From Confirmed Severe Asthma to Active Therapy

1. 01→Confirm Severe, Refractory AsthmaInhaler technique, adherence, and contributing conditions are addressed first, so that biologic therapy is considered only once poor control is genuinely refractory.↓
2. 02→Gather BiomarkersBlood eosinophil count, FeNO, allergic sensitization and IgE level, and exacerbation history are reviewed together.↓
3. 03Identify the Active PathwayBiomarker results point toward which inflammatory pathway, IgE, IL-5, IL-4/IL-13, or TSLP, is most active in that patient's asthma.↓
4. 04→Select a Matching BiologicA biologic targeting that pathway is chosen, weighed against practical factors such as injection frequency and administration setting.↓
5. 05Initiate and Monitor ResponseTherapy begins, with response assessed over months by exacerbation frequency, oral steroid need, and day-to-day symptom control.

Phenotype-Directed Therapy: The Core Modern Concept

The central idea behind modern severe asthma management is that asthma is not one uniform disease but a collection of related conditions with different underlying inflammatory drivers, often described as phenotypes or endotypes.

A patient whose asthma is driven predominantly by allergic, IgE-mediated mechanisms has a meaningfully different disease process from a patient whose asthma is driven predominantly by eosinophil-rich, type 2 inflammation without a clear allergic trigger, even though both may look similar day to day in terms of symptoms.

Biologics were developed against this backdrop, each targeting a distinct point along the inflammatory cascade. Choosing among them is therefore not a matter of picking whichever drug is newest or most commonly prescribed; it depends on identifying, through a combination of history and biomarker testing, which inflammatory pathway is most active in a given patient’s asthma.

This phenotype-directed approach is what separates biologic selection from most other areas of asthma treatment, where a stepwise, largely uniform approach applies to most patients.

The IgE Pathway: Anti-IgE Therapy

The first biologic developed for asthma targeted immunoglobulin E (IgE), the antibody class responsible for classic allergic reactions. Omalizumab (Xolair) remains the class-founding example of anti-IgE therapy.

The IL-5 / IL-5 Receptor Pathway: Anti-IL-5 and Anti-IL-5-Receptor Therapy

A separate group of biologics targets interleukin-5 (IL-5), a signaling protein that is central to the development, survival, and activation of eosinophils, a type of white blood cell strongly implicated in airway inflammation for a substantial subset of people with severe asthma. Three agents are currently available in this class, differing slightly in mechanism:

Mepolizumab (Nucala)

Binds IL-5 directly, reducing the signal that sustains eosinophil populations.

Reslizumab (Cinqair)

Also binds IL-5 directly, reducing the signal that sustains eosinophil populations.

Benralizumab (Fasenra)

Blocks the IL-5 receptor on the surface of eosinophils, interrupting IL-5 signaling and promoting more direct depletion of circulating eosinophils.

This class is generally directed at eosinophilic asthma, identified primarily through an elevated blood eosinophil count, typically assessed on standard bloodwork, together with a history of exacerbations despite optimized inhaled therapy. Reducing eosinophil-driven inflammation through this pathway has been associated with meaningful reductions in exacerbation frequency for appropriately selected patients.

The IL-4/IL-13 Pathway: Anti-IL-4-Receptor-Alpha Therapy

Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two related cytokines that both signal through a shared receptor component, the alpha subunit of the IL-4 receptor.

The TSLP Pathway: Anti-TSLP Therapy

The most recently established pathway among these therapy classes targets thymic stromal lymphopoietin (TSLP), a signaling molecule released by the epithelial cells that line the airway, positioned further upstream in the inflammatory cascade than IgE, IL-5, or IL-4/IL-13.

Comparing the Biologic Classes

The four sections above describe each inflammatory pathway individually; the table below lines them up side by side using the same mechanism, representative agent, and candidate-profile details already covered.

Asthma Biologic Classes at a Glance

Asthma Biologic Classes at a Glance

Dimension	Anti-IgE	Anti-IL-5 / Anti-IL-5-Receptor	Anti-IL-4-Receptor-Alpha	Anti-TSLP
Representative Agent(s)	Omalizumab (Xolair)	Mepolizumab (Nucala), reslizumab (Cinqair), benralizumab (Fasenra)	Dupilumab (Dupixent)	Tezepelumab (Tezspire)
Mechanism	Binds circulating IgE, reducing IgE-mediated activation of mast cells and other allergic-response cells	Binds IL-5 directly or blocks the IL-5 receptor on eosinophils, reducing eosinophil survival and activity	Blocks the shared IL-4/IL-13 receptor subunit, interrupting both signaling pathways at once	Blocks TSLP, an upstream epithelial-derived signal that helps initiate the type 2 inflammatory cascade
Position in the Cascade	Downstream, at the point of allergic cell activation	Downstream, at the point of eosinophil survival and activity	Downstream, at a shared cytokine-receptor step	Further upstream than IgE, IL-5, or IL-4/IL-13
Typical Candidate Profile	Allergic (IgE-driven) asthma with confirmed sensitization to a perennial allergen and elevated IgE within a labeled range	Eosinophilic asthma with an elevated blood eosinophil count and a history of exacerbations	Type 2 inflammation more broadly, including eosinophilic and/or allergic features, sometimes with overlapping atopic conditions	Broader eligibility profile, considered for severe asthma without requiring a single specific biomarker threshold to be met

Biomarkers That Guide Biologic Selection

Selecting among biologic classes depends on a handful of biomarkers and clinical factors, gathered and interpreted together rather than in isolation, including results from FeNO testing:

Blood Eosinophil Count

A standard blood test that measures the number of circulating eosinophils, used to identify eosinophilic asthma and to help gauge how likely a patient is to respond to IL-5-pathway or IL-4/IL-13-pathway therapies.

FeNO Level

Measures nitric oxide in exhaled breath as a marker of type 2 airway inflammation; an elevated result can support the case for therapies effective against type 2-driven disease.

Allergic Sensitization and IgE Level

Allergy testing results, combined with a total IgE level, help determine whether anti-IgE therapy is a biomarker-appropriate option.

Exacerbation History

How often a patient has needed oral corticosteroid courses, urgent care visits, or hospitalization for asthma factors heavily into both the decision to consider a biologic at all and, in some cases, which agent's labeled criteria a patient meets.

Because these biomarkers can overlap, meaning a patient can have both an elevated eosinophil count and confirmed allergic sensitization, more than one biologic class may technically be an option for many patients, at which point additional factors, discussed below, help guide the final choice.

Reducing Oral Corticosteroid Burden

For patients who require chronic oral corticosteroids to control their asthma, reducing or eliminating that requirement is one of the central goals of biologic therapy, and often one of the most meaningful outcomes for the patient. Long-term oral steroid use carries a well-documented, cumulative health cost across multiple body systems, including:

• Bone density
• Blood sugar and diabetes risk
• Weight
• Adrenal function
• Cataracts
• Cardiovascular health

Many, though not all, patients who begin an appropriately matched biologic and achieve improved asthma control are able to taper their oral steroid dose over time. This tapering is managed gradually and individually by a physician, monitoring for both continued asthma control and, when relevant, adrenal function, and is never something a patient should attempt to adjust independently.

How Biologics Are Given

These practical differences in administration are legitimate factors that patients and clinicians weigh alongside biomarker fit when choosing among biologics that might otherwise be similarly appropriate on clinical grounds:

• Injection frequency
• Whether home self-injection is an option
• Whether infusion visits are required

How Response Is Assessed

Why the Right Choice Differs Between Patients

Asthma Biologic Care at VitalAir

Evaluating whether a biologic may be appropriate starts with confirming a diagnosis of severe asthma, reviewing prior treatment history and inhaler technique, and gathering the biomarker information, including blood eosinophil count, FeNO, and allergic testing, needed to identify a likely phenotype. The VitalAir Sleep & Lung Center serves patients throughout Frisco, Texas and the greater North Dallas–Fort Worth area; a pulmonary evaluation is the starting point for determining whether biologic therapy, further inhaled treatment optimization, or another approach best fits your specific asthma.